In patients with severe hypertension, chronic heart failure or a history of stroke, the lower limit of autoregulation of cerebral blood flow (CBF) is shifted to higher levels of blood pressure (BP) than those observed in healthy subjects. The aim of pharmacotherapy for hypertensive patients with an impaired autoregulation of CBF should be to reduce BP while preserving an appropriate CBF. In the present study, 16 hypertensive patients who had had an episode of stroke more than 4 weeks previously were administered the angiotensin II (AT 1 ) receptor antagonist losartan at daily doses of 25-100 mg for 4 weeks. Systolic and diastolic blood pressures were recorded for 24 h using an ambulatory BP monitoring system. CBF in both hemispheres of the cerebrum and cerebellum was quantified using single photon emission tomography with N-isopropyl-p-[ 123 I]iodoamphetamine. At baseline, CBF was 29.776.7 ml/min/100 g in the cerebrum and 31.577.5 ml/min/100 g in the cerebellum. At the end of treatment, BP was lower, while CBF increased by 7.7% in the cerebrum, and remained at the baseline level in the cerebellum. Thus, CBF was preserved despite the reduction in BP. We consider the use of losartan is advantageous for hypertensive patients with a history of stroke in whom autoregulation of CBF is potentially impaired.
Introduction
It is well known that cerebral blood flow (CBF) in healthy subjects is autoregulated to maintain a stable flow rate within a wide range of changes in blood pressure (BP), with the lower limit of mean BP being as low as 50-60 mmHg. However, in patients with severe hypertension, CBF is affected when the mean BP decreases below 100 mmHg. 1 Furthermore, in patients with a cerebrovascular disease, the autoregulation of CBF may be disturbed so that the lower limit necessary to maintain a constant CBF is shifted to a BP level higher than that seen in healthy subjects. 2, 3 This impaired autoregulation is considered to be mostly a consequence of structural damage of small arteries in the brain, accompanying with higher susceptibility to vasoactive substances.
On the basis of knowledge of the actions of angiotensin II on vascular beds in organs including the brain, therapeutic benefits of intervention of the renin-angiotensin system has been considered to normalize the lower limit of CBF autoregulation in patients with an impaired cerebral circulation. The ACE inhibitor captopril was the first drug to maintain CBF while BP was reduced beyond lower limit of autoregulation in hypertensive rats. 4, 5 Similar results were obtained in patients with chronic heart failure. 6, 7 In 1992, Kuriyama et al 8 reported that the ACE inhibitor enalapril preserved CBF in hypertensive patients with an old history of stroke with effectively reducing BP, indicating successful shifting of the lower limit of CBF autoregulation to lower BP levels. These findings led us to postulate that a direct blockade of angiotensin II receptors may result in a reduction of BP while maintaining an appropriate CBF in patients whose autoregulation is impaired.
In the present study, we assessed the effect of the angiotensin II (AT 1 ) receptor antagonist (AIIA) losartan on CBF in hypertensive patients with a history of stroke. We used an ambulatory BP monitoring (ABPM) system to measure BP, and single photon emission computed tomography (SPECT) with the tracer N-isopropyl-p-[
123 I]iodoamphetamine to measure the blood flow in both hemispheres of the cerebrum and cerebellum.
Patients and methods

Study patients
In-patients and outpatients of either gender, X20-o75 years old, who had hypertension and a history of stroke were eligible for the study, provided they satisfied the following criteria during a pretreatment screening period of 2 days-one week.
(a) Hypertensive patients. That is, their systolic BP (SBP) and diastolic BP (DBP) in the supine position measured using a mercury sphygmomanometer, at least twice on their visits to the hospital, were X140 or X90 mmHg, respectively, and average 24 h ambulatory SBP (24-h SBP) during the screening period was X135 mmHg or their average 24 h DBP (24-h DBP) was X85 mmHg. (b) Patients with a chronic cerebrovascular disease.
That is, the patients who had had an episode of stroke (cerebral infarction, defined by X-ray computed tomography or magnetic resonance imaging), more than 4 weeks, previously.
The principal investigator decided the eligibility of the patients. Exclusion criteria were as follows: 
Study design
The overview of the study design is shown in Figure 1 . This study was designed as a self-control study by comparing values of BP and CBF on weeks 2 and 4 of treatment to those observed during the screening period (baseline) in each patient. Before the screening period, a washout period of at least 2 weeks was required for the patients who had been treated with antihypertensive drugs. Following the screening period, the patients were administered losartan once daily at the starting dose of 25 mg. However, in cases in which a patient's compliance was judged by investigator(s) to be sufficiently good for the administration of a higher dose, a starting dose of 50 mg was applied. Thus, in the first 2 weeks the dose of losartan was 25 or 50 mg. In the following 2 weeks, however, the dose was escalated if the 24-h SBP/DBP of o135/85 mmHg was not achieved, or if reductions in 24-h SBP of X10 mmHg and 24-h DBP of X5 mmHg were not satisfied.
BP was recorded by ABPM and CBF was measured by SPECT during the screening period, and at weeks 2 and 4 of treatment. To measure 24-h BP, the patients were fitted with an ABPM and the pressure was recorded every 30 min from 0600 to 2200 (daytime) and every 60 min from 2200 to 0600 (nighttime). For measurements of the 24-h BP, the ABPM device Type TM-2421(A&D Co. Ltd., Tokyo, Japan) was used. CBF was evaluated using the N-isopropyl-p-[
123 I]iodoamphetamine ( 123 I-IMP) autoradiographic method based on a two-compartment kinetic model in which the input function is determined by arterial counting 10 min after the injection of 123 I-IMP instead of frequent blood sampling. The absolute value was obtained by the table look-up method after the arterial count was converted to the scale of the SPECT count using a cross calibration factor that was determined a priori in a phantom study. 9, 10 SPECT was performed using a ring-type gamma camera (Headtome SET-070; Shimadzu, Kyoto, Japan) with an 8-mm FWHM obtained. Patients were immobilized with eyes covered, and 4.5 mCi (166.5 MBq) of 123 I-IMP was injected intravenously. Data collection began 15 min after injection of the tracer. Image data over 30-min were collected onto a 128 Â 128 matrix using a general all-purpose collimator. All data were corrected for an attenuation of 0.1/cm and tomographic data were reconstructed using a filtered back-projection algorithm. The regions of interest (ROIs) were drawn on the both sides of middle cerebral artery territories and cerebellar hemispheres according to our previous report.
11 These ROIs were defined with reference to the atlas of Kretschmann and Weinrich. 12 If an infarct was included within a standard ROI, the size of the ROI was reduced to avoid the area of infarct.
The study protocol was in accordance with the declaration of Helsinki and was reviewed and approved by the Institutional Review Board of the Figure 1 Study design for treatment of hypertensive patients with a history of stroke. *Patients who had been treated with any antihypertensive drug were entered after a washout period of at least 2 weeks. **Two-day to 1-week screening period was followed by the treatment period of 4 weeks. CBF was measured by SPECT and mean 24-h BP by ABPM during the screening period, and the last days of weeks 2 and 4. ***When BP control was inadequate within the first 2 weeks (see Study design), the dose of losartan was escalated.
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National Cardiovascular Center. Written informed consent was obtained from all enrolled patients.
Statistics
All values are expressed as the mean7s.d. Differences of values on weeks 2 and 4 from the respective baseline values were analysed by one-sample t-test. Differences with a P-value of o0.05 were considered statistically significant.
Results
Patient characteristics at baseline and at week 4
We enrolled 16 patients in the study. One patient showed increases in AST (GOT) and g-GTP at the week-2 determination point and the principal investigator considered it was desirable for this patient to discontinue the treatment. Changes of CBF were therefore assessed in 15 patients. 
Cerebral blood flow
Types of cerebrovascular disease (CVD) of our patients were atherothrombotic brain infarction (ATBI), lacunar infarction (LA), cardioembolic infarction (CE), and aortogenic infarction (Aorta). There were three patients who had periventricular hyperintensity (PVH). There was no specific trend in response to losartan in relation to CVD types. CBF values of individual patients measured at week 4 are summarized in Table 1 . Figure 3 shows global blood flow in the cerebrum and cerebellum, at baseline and after 4 weeks of treatment with losartan. The average blood flow in the cerebrum increased by 7.7% (from 29.776.7 to 32.078.0 ml/min/100 g) with statistical significance (Po0.05), while in the cerebellum the blood flow remained unchanged (from 31.577.5 to 33.478.7 ml/min/100 g; NS).
We next divided the patients into two subgroups based on their responsiveness of BP to losartan. The upper panels of Figure 4 show the change in CBF in the cerebellum and cerebrum of the eight patients who showed an effective decrease of 24-h SBP and 24-h DBP (subgroup A). In this subgroup the increase in CBF in the cerebrum was statistically significant. The lower panels of Figure 4 show the CBF in the cerebellum and cerebrum of the seven patients in whom no decrease of 24-h SBP and 24-h DBP was observed (subgroup B). CBF did not increase and remained unchanged, although two patients in this subgroup showed prominent increases; one from 35.8 to 43.1 (20.4%) and the other from 40.0 to 50.5 ml/min/100 g (26.3%) in the cerebellum, and from 34.4 to 42.4 (23.3%) and 38.2 to 49.9 (30.6%) in the cerebrum, respectively.
Serum uric acid and safety evaluation
Laboratory measurements revealed a statistically significant decrease in serum uric acid in all 
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patients: the average concentration of serum uric acid was 356.9749.2 mmol/l at baseline and 312.5756.5 mmol/l at week 4 (12% reduction, Po0.01). As for adverse effects, six patients reported experiences that were considered by the investigator to be possibly or probably related to the study treatment. The patient who was dropped out of the study showed an increase in AST (GOT) from 51 to 72 IU/l and of g-GTP from 296 to 380 IU/l and vomiting in the first 2-weeks of losartan treatment. In another patient, slight increases in AST (GOT) from 30 to 65 IU/l and ALT (GPT) from 24 to 69 IU/l and g-GTP from 215 to 348 IU/l were observed. In four other patients, dizziness, transient loss of consciousness, diarrhea and swelling and tenderness of the right hand were reported. No severe or fatal adverse events were observed during the 4 weeks of treatment with losartan.
Discussion
In our present study, treatment of hypertensive patients with a history of stroke for 4 weeks with losartan resulted in an effective average reduction of 13.7 mmHg in 24-h SBP and of 8.1 mmHg in 24-h DBP, as measured using an ABPM system. Whereas, the average blood flow in the cerebrum showed a statistically significant increase. The average blood flow in the cerebellum tended to increase, but the increase did not reach statistical significance. Thus, the blood flow in both cerebrum and cerebellum was well preserved, despite the decrease of BP. However, there were seven patients who showed only a 2.1 mmHg decrease in 24-h SBP, and a 2.0 mmHg decrease in 24-h DBP. As a result, of a total of 15 patients, eight were well responded and seven were poorly responded to losartan. Although there was no statistical correlation between the change in BP and the change in CBF, in patients whose BPs were reduced, only one had a reduced flow in the cerebrum, while in patients whose BPs were poorly reduced, three had the reduced flow ( Figure 4) . These results led us to postulate that the more effectively losartan reduces BP, the more favourably CBF is preserved. In our patients the average baseline CBF, excluding the area of infarct, was 29.776.7 ml/ min/100 g in the cerebrum and 31.577.5 ml/min/ 100 g in the cerebellum. Kuriyama et al 8 reported that global CBF in patients with a history of stroke and impaired autoregulation was 42.376.1 ml/min/100 g. Iida et al 10 reported CBF was 39.072.9 ml/min/100 g in the cerebellum of healthy volunteers. By comparison, the CBF of our patients was low, indicating an impaired cerebral circulation.
The beneficial effect of ACE inhibition on CBF was first reported by Barry et al 4 and Jarden et al 5 in hypertensive rats, using captopril. They demonstrated that although BP fell below the previously established lower limit of autoregulation, CBF remained unchanged. Clinical evidences of this Upper panels correspond to subgroup A (BP was reduced; n ¼ 8) and the lower panels to subgroup B (BP was not reduced; n ¼ 7). A circle with a bar represents the mean value 7s.d. In subgroup A, the increase in CBF was statistically significant in the cerebrum (*Po0.05 vs baseline).
Preservation of cerebral blood flow by losartan H Moriwaki et al effect of ACE inhibitors was obtained in patients with chronic heart failure, 6, 7 and then in hypertensive patients with a history of stroke. 8 Our present results are consistent with such previous findings, thereby the effect of ACE inhibitors to preserve CBF is probably attributed to the interference of angiotensin II AT 1 receptor mediated actions, since losartan is a selective angiotensin II AT 1 receptor antagonist (AIIA). The important role of angotensin II AT1 receptors to affect CBF is also supported by the results reported by Nishimura et al, 13 who demonstrated the effect of the AIIA candesartan to preserve CBF in spontaneously hypertensive rats with cerebral ischaemia. Furthermore, the effect of repeated administration of losartan may differ from that of ACE inhibitors. Recent advances in interventional pharmacology of the renin-angiotensin system have revealed clear differences between the properties of AIIAs and those of ACE inhibitors. First, AIIAs inhibit angiotensin II AT 1 receptors, but not AT 2 receptors which may counteract the actions of AT 1 receptors.
14 The actions of AT 2 are considered to include vasodilation, induction of apoptosis, interference of vascular remodeling, all which may contribute to preserve the vascular structure. 15 However, ACE inhibitors cannot block the production of angiotensin II via a non-ACE enzyme, such as chymase, which is known to exist in the vascular tissue. 16, 17 Taken together, the beneficial effect of losartan in hypertensive patients with a history of stroke may be explained by its acute effect that is similar to that of ACE inhibitors, as well as by its chronic effect on vascular tissue, through which it ameliorates its structure and function. If the latter were the case, it is considered that the effects of a blockade of angiotensin II AT 1 receptors by losartan are amelioration of the damaged vascular structure and restoration of a physiologically normal tone in resistant arteries; thereby the lower limit of autoregulation would be reset to a level of BP lower than that established as a consequence of stroke. These assumptions must be substantially demonstrated in the future in both experimental and clinical studies.
Recently, an interesting clinical study involving hypertensive patients with left ventricular hypertrophy, named LIFE study, was reported. 18 In this study, 4588 patients were treated with the beta-blocker atenolol and 4605 patients with the AIIA losartan, for more than 60 months. The efficacy of these drugs regarding BP reduction was similar. However, the proportion of patients with first event of stroke was significantly lower in the losartan group than in the atenolol group. The investigators of this mega-trial did not state the reason for this difference, but it may be possible that losartan reduced the risk of infarction by protecting cerebral vessels from structural changes. If this were the case, the result of our present study would be compatible with the result of the LIFE study in terms of protection of function and structure of vascular beds in the brain.
In conclusion, administration of losartan to hypertensive patients with a history of stroke for four consecutive weeks resulted in a decrease of BP with a preserved blood flow in both the cerebrum and cerebellum. The blockade of angiotensin II AT 1 receptors by losartan is considered to be safe in such patients, because it preserves the function of autoregulation of cerebral blood flow in therapy of BP control.
